1. Panzgram G. Mortality and survival in type 2 (non-insulin dependent) diabetes mellitus. Diabetologia 1987; 30: 123–31.
2. International Diabetes Federation. New diabetes figures. Press release, 25 August 2003. www.idf.org/homr/index.cfm.
3. Nathan DM, Buse JB, Davidson MB et al. Medical management of hyperglycemia in type 2 diabetes: A Consensus Algorithm for the initiation and adjustment oh therapy. A consensus statement of the ADA/EASD. Diabetes Care 32: 193–203.
4. The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of Intensive glucose Lowering in Type 2 Diabetes. NEJM 2008; 358: 2545–59.
5. Marre M, Howlett H, Lehert P et al. Improved glycaemic control with metformin-glybenclamide combined therapy (Glucovance) in type 2 diabetic patients inadequately controlled on metformin. Diabetic Med 19: 673–80.
6. Feinglos M, Dailey G, Cefalu et al. Efect on glycemic control by addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabet Res Clin Pract 2005; 68: 167–75.
7. Charpentier G, Fleury F, Kabir M et al. improved glycaemic control by addition of glymepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med 2001; 18: 828–34.
8. Moses R, Slobodniuk R, Boyages S. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabet Care 22: 119–24.
9. Einhorn D, Rendell M, Rosenzweig J et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group. Clin Therapeut 22: 1395–409.
10. Fonseca V, Rosenstock J, Patwardhan R et al. Effect of Metformin and Rosiglitazone Combination Therapy in Patients With Type 2 Diabetes Mellitus: A Randomized Controlled Trial. JAMA 283: 1695–702.
11. Rosenstock J, Brown A, Fischer J et al. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabet Care 21: 2050–5.
12. Bosi et al. Effects of Vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabet Care 2007; 30: 890–5.
13. Charbonnel B, Karasik A, Liu J et al. Efficacy and Safety of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Added to Ongoing Metformin Therapy in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Alone. Diabet Care 2006; 29 (12): 2638–43.
14. DeFronzo RA, Ratner RE, Han J et al. Effects of Exenatide (Exendin-4) on Glycemic Control and Weight Over 30 Weeks in Metformin-Treated Patients With Type 2 Diabetes. Diabet Care 28: 1092–100.
15. Nathan DM, Davidson MB, DeFronzo R et al. Impaired fasting glucose and impaired glucose tolerance. Implications for care. Diabet Care 30: 753–9.
16. Knowler W, Barrett-Connor E, Fowler SE et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393–403.
17. Chiasson JL, Josse RG, Gomis R et al. The STOPNIDDM Trial Research Group: Acarbose for prevention of type 2 diabetes metlitus: the STOP-NIDDM randomized trial. Lancet 2002; 359: 2072–7.
18. Lindstrom J, Louheranta A, Mannelin M et al. The Finnish Diabetes Prevention Study (DPS): Lifestyle intervention and 3-year results on diet and physical activity. Diabet Care 2003; 26: 3230–6.
19. Pan XR, Li GW, Hu YH et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabet Care 1997; 20: 537–44.
20. Gerstein HC, Yusuf S, Boxch J, Pogue J et al. DREAM (Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication) Trial Investigators: effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 2006; 368: 1096–105.
21. Buchanan TA, Xiang AH, Peters RK et al. Preservation of pancreatic _-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes 2002; 51: 2796–803.
22. Torgerson JS, Hauptman J, Boldrin MN et al. Xenical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care 2004; 27: 151–61.
23. Alberti K, Zimmet P, Shaw J. International Diabetes Federation: a consensus on Type 2 diabetes prevention. Diabet Med 2007; 24: 451–63.
24. American Diabetes Association. Standards of Medical Care in Diabetes-2009. Diabet Care 2009; 32 (Suppl. 1): S13–61.
25. Карпов О.И. Клинико-фармакологические аспекты титрования дозы метформина. Сахарный диабет. 2007; 3: 53–6.
26. Misbin RI et al. Lactic Acidosis in Patients With Diabetes Treared with Metformin. N Engl J Med 1998; 338: 265–6.
27. Salpeter S, Greyber E, Pasternak G et al. Risk of fatal and non-fatal lactic acidosis with metformin in type 2 diabetes. Cochrane Database Syst Rev 2003; 2: CD002967.
28. Salpeter SR, Greyber E, Pasternak GA et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003; 163 (21): 2594–602.
29. Misbin R. The Phantom of Lactic Acidosis due to Metformin in Patients With Diabetes. Diabetes Care 2004; 27: 1791–3.
30. Bowker SL et al. Increased cancer-related mortality for patients with type 2 diabetes who use sulfonilureas or insulin. Diabet Care 2006; 29: 254–8.
31. UK Prospective Diabete Study Group. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854–65.
32. Libby G, Donnelly LA et al. New users of metformin are at low risk of incidenr cancer. Diabet Care 2009; 32: 1620–5.
33. Smith U, Gale M. Does diabetes therapy influence the risk of cancer? Diabetologia 2009; 52: 1669–708.
34. Недосугова Л.В. Эффективность метформина в профилактике сердечно-сосудистой патологии при сахарном диабете типа 2 и метаболическом синдроме. Consilium Medicum. 2009; 11 (5): 102–9.